Esperion (ESPR) CLO Benjamin Looker Sells 5,708 Shares

What Happened

• Benjamin Looker, Chief Legal Officer of Esperion Therapeutics (ESPR), sold 5,708 shares on March 17, 2026 at $2.70 per share, generating $15,429 in proceeds. The sale is reported as an open market or private sale and was made to satisfy tax obligations on vested restricted stock units (RSUs).

Key Details

• Transaction date and price: 2026-03-17, 5,708 shares at $2.70 each.
• Total proceeds: $15,429.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: F1 — shares were sold to satisfy tax obligation on vested RSUs (tax withholding).
• Filing: Form 4 filed 2026-03-18 for the 2026-03-17 transaction (timely within normal reporting window).
• Transaction code: S (Sale).

Context

• This sale was a tax-withholding sale tied to vested RSUs, a routine corporate practice and not the same signal as a discretionary sell-for-diversification or portfolio reasons. The small dollar value suggests it is administrative rather than a material insider directional trade.